Werewolf Therapeutics, Inc. (NASDAQ:HOWL) combines selective tumor targeting, masking, and validated linker technology with ...

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

A 10% owner of Werewolf Therapeutics Inc (NASDAQ:HOWL), including MPM Asset Management LLC and related entities, reported selling 160,103 shares of common stock over three days, according to a Form 4 ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...